Mucus Relief Dm Tablet, Extended Release
NDC Package 21130-997-67

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Mucus Relief Dm (guaifenesin and dextromethorphan hbr) tablets is do not crush, chew, or break tablettake with a full glass of waterthis product can be administered without regard for timing of mealsadults and children 12 years and older: 1 or 2 tablets every 12 hours; not more than 4 tablets in 24 hourschildren under 12 years of age: do not use. This formulation utilizes a tablet, extended release delivery system. Marketed by Better Living Brands Llc, this product is identified by NDC 21130-997 and is authorized under FDA application ANDA206941.

Identification & Billing

NDC Package Code
21130-997-67
Package Description
2 BLISTER PACK in 1 CARTON / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK
Product Code
11-Digit Billing Format
21130099767
RxNorm Crosswalk
  • RxCUI: 1298324 - guaiFENesin 600 MG / dextromethorphan HBr 30 MG 12HR Extended Release Oral Tablet
  • RxCUI: 1298324 - 12 HR dextromethorphan hydrobromide 30 MG / guaifenesin 600 MG Extended Release Oral Tablet
  • RxCUI: 1298324 - dextromethorphan hydrobromide 30 MG / guaifenesin 600 MG 12 HR Extended Release Oral Tablet

Clinical Specifications

Proprietary Name
Mucus Relief Dm
Non-Proprietary Name
Guaifenesin And Dextromethorphan Hbr
Substance Name
Dextromethorphan Hydrobromide; Guaifenesin
Dosage Form
Tablet, Extended Release - A solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Usage Information
Do not crush, chew, or break tablettake with a full glass of waterthis product can be administered without regard for timing of mealsadults and children 12 years and older: 1 or 2 tablets every 12 hours; not more than 4 tablets in 24 hourschildren under 12 years of age: do not use

Regulatory & Marketing

Labeler Name
Better Living Brands Llc
Product Type
Human Otc Drug
FDA Application #
ANDA206941
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-17-2017
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 21130-997-67 identifies a specific commercial package of 2 blister pack in 1 carton / 10 tablet, extended release in 1 blister pack of Mucus Relief Dm, a human over the counter drug labeled by Better Living Brands Llc. This tablet, extended release is formulated for oral use and contains dextromethorphan hydrobromide; guaifenesin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Better Living Brands Llc on March 17, 2017. The current certification is valid through December 31, 2026.

How is this Better Living Brands Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 21130099767. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
21130-997-67
11-Digit CMS (5-4-2)
21130-0997-67

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.